Trial · NCT00704288
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
NCT00704288, Phase 2, Completed, Exelixis; results first posted 2024-02-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme. Trials, record NCT00704288. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00704288
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
- NCT number
- NCT00704288
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 222 participants, actual
- Lead sponsor
- Exelixis
- Conditions
- Glioblastoma Multiforme
- Interventions
- XL184
- First posted
- 2008-06-24
- Last updated
- 2024-02-05
- Results first posted
- 2024-02-05
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | 8 weeks until progressive disease | Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features |
| Secondary | Duration of Objective Response (Months) | Assessed during periodically scheduled visits until progressive disease | Duration of response is defined as the time from the first documentation of objective response that was subsequently confirmed at a visit that was ≥ 28 days later to disease progression or death due to any cause. |
| Secondary | Progression Free Survival (PFS) | Assessed during periodically scheduled visits until progressive disease | Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features |
| Secondary | Overall Survival (OS) | Assessed during periodically scheduled visits until progressive disease | Overall survival (OS) is defined as the time from first dose to death due to any cause. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate (ORR) | 8 weeks until progressive disease | percentage of participants | NUMBER | |
| SECONDARY | Duration of Objective Response (Months) | Assessed during periodically scheduled visits until progressive disease | Insufficient number of participants with events | Months | MEDIAN |
| SECONDARY | Progression Free Survival (PFS) | Assessed during periodically scheduled visits until progressive disease | Months | MEDIAN | |
| SECONDARY | Overall Survival (OS) | Assessed during periodically scheduled visits until progressive disease | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group23
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Treatment Group A1 (175 mg) - Naive | 17.6 | percentage of participants | ||
| Objective Response Rate (ORR) | Treatment Group B1 (125 mg) - Naive | 27.0 | percentage of participants | ||
| Objective Response Rate (ORR) | Treatment Group C1 (125 mg) - Naive | 8.8 | percentage of participants | ||
| Objective Response Rate (ORR) | Treatment Group A2 (175 mg) - Pre-Treated | 8.3 | percentage of participants | ||
| Objective Response Rate (ORR) | Treatment Group B2 (125 mg) - Pre-Treated | 0 | percentage of participants | ||
| Objective Response Rate (ORR) | Treatment Group C2 (125 mg) - Pre-Treated | 5.6 | percentage of participants | ||
| Duration of Objective Response (Months) | Treatment Group A1 (175 mg) - Naive | 5.913 | 95% Confidence Interval 2.760 to 12.812 | Months | |
| Duration of Objective Response (Months) | Treatment Group B1 (125 mg) - Naive | 8.541 | 95% Confidence Interval 3.778 to 9.264 | Months | |
| Duration of Objective Response (Months) | Treatment Group C1 (125 mg) - Naive | NA | 95% Confidence Interval 2.792 to NA | Months | |
| Duration of Objective Response (Months) | Treatment Group A2 (175 mg) - Pre-Treated | NA | 95% Confidence Interval NA to NA | Months |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 results by groupParticipant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Treatment Period | STARTED | Treatment Group A (175 mg) | 46 | |
| Overall Treatment Period | STARTED | Treatment Group B (125 mg) | 59 | |
| Overall Treatment Period | STARTED | Treatment Group C (125 mg) | 117 | |
| Overall Treatment Period | Naïve | Treatment Group A (175 mg) | 34 | |
| Overall Treatment Period | Naïve | Treatment Group B (125 mg) | 37 | |
| Overall Treatment Period | Naïve | Treatment Group C (125 mg) | 81 | |
| Overall Treatment Period | Pre-treated | Treatment Group A (175 mg) | 12 | |
| Overall Treatment Period | Pre-treated | Treatment Group B (125 mg) | 22 | |
| Overall Treatment Period | Pre-treated | Treatment Group C (125 mg) | 36 | |
| Overall Treatment Period | COMPLETED | Treatment Group A (175 mg) | 0 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events452
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Treatment Group A (175 mg) | 35 | 46 | |
| other | Fatigue | General disorders | Treatment Group B + Group C (125 mg) | 132 | 176 | |
| other | Diarrhoea | Gastrointestinal disorders | Treatment Group A (175 mg) | 31 | 46 | |
| other | Diarrhoea | Gastrointestinal disorders | Treatment Group B + Group C (125 mg) | 97 | 176 | |
| other | Decreased Appetite | Metabolism and nutrition disorders | Treatment Group A (175 mg) | 22 | 46 | |
| other | Decreased Appetite | Metabolism and nutrition disorders | Treatment Group B + Group C (125 mg) | 66 | 176 | |
| other | Nausea | Gastrointestinal disorders | Treatment Group A (175 mg) | 17 | 46 | |
| other | Nausea | Gastrointestinal disorders | Treatment Group B + Group C (125 mg) | 65 | 176 | |
| other | Headache | Nervous system disorders | Treatment Group A (175 mg) | 20 | 46 | |
| other | Headache | Nervous system disorders | Treatment Group B + Group C (125 mg) | 59 | 176 |
1 to 10 of 452Source ClinicalTrials.gov
See all 452 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Group A (175 mg) | 41 | 46 |
| Total, all-cause mortality | Treatment Group B + Group C (125 mg) | 144 | 176 |
| Total, other adverse events | Treatment Group A (175 mg) | 46 | 46 |
| Total, other adverse events | Treatment Group B + Group C (125 mg) | 176 | 176 |
| Total, serious adverse events | Treatment Group A (175 mg) | 24 | 46 |
| Total, serious adverse events | Treatment Group B + Group C (125 mg) | 90 | 176 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Treatment Group A (175 mg) vs Treatment Group B + Group C (125 mg): deaths from any cause | Trial comparisons |
| Treatment Group A (175 mg) vs Treatment Group B + Group C (125 mg): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00704288
GET https://conductscience.org/api/trials/v1/NCT00704288/results?page=2